Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

NCT01628445 · Terminated

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide helps lower blood sugar levels in adults with type 2 diabetes who are already using insulin.

Status Terminated Stopped early and will not restart.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 52 people

Who can join Ages 18–80 · all sexes

Timeline Started 2012-08 · est. completion 2015-11

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT01628445 ↗

Description as written by the study sponsor.

Liraglutide is a GLP1 agonist used in the treatment of Type 2 diabetes and is is asociated with improved blood glucose control, weight loss and low rates of hypoglycemia when used alone or in combination with metformin. Liraglutide has not been extensively tested in people with type 2 diabetes who are taking relatively large doses of insulin (\>50 U/day). Often these patients are insulin resistant and despite using large doses of insulin are not able to achieve glucose targets. The rationale for this study is to assess if the addition of liraglutide in addition to usual care versus placebo can improve blood glucose levels in people not achieving a target HbA1C of less than 7.0%.

Treatments tested

liraglutide also known as Victoza Drug

liraglutide titrated to 1.8 mg sc daily
placebo injection also known as Placebo Drug

placebo injected sc daily volume equal to active comparator

Main thing measured	Change in A1c
Sponsor	University of Manitoba
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01628445 ↗